Bupi Yishen Formula Versus Losartan for Non-Diabetic Stage 4 Chronic Kidney Disease: A Randomized Controlled Trial.
Mao W, Yang N, Zhang L, Li C, Wu Y, Ouyang W, Xu P, Zou C, Pei C, Shi W, Zhan J, Yang H, Chen H, Wang X, Tian Y, Yuan F, Sun W, Xiong G, Chen M, Guan J, Tang S, Zhang C, Liu Y, Deng Y, Lin Q, Lu F, Hong W, Yang A, Fang J, Rao J, Wang L, Bao K, Lin F, Xu Y, Lu Z, Su G, Zhang L, Johnson DW, Zhao D, Hou H, Fu L, Guo X, Yang L, Qin X, Wen Z, Liu X.
Mao W, et al.
Front Pharmacol. 2021 Jan 29;11:627185. doi: 10.3389/fphar.2020.627185. eCollection 2020.
Front Pharmacol. 2021.
PMID: 33708125
Free PMC article.
Chinese herbal medicine (CHM) might have benefits in patients with non-diabetic chronic kidney disease (CKD), but there is a lack of high-quality evidence, especially in CKD4. This study aimed to assess the efficacy and safety of Bupi Yishen Formula (BYF) vs. losartan in p …
Chinese herbal medicine (CHM) might have benefits in patients with non-diabetic chronic kidney disease (CKD), but there is a lack of high-qu …